Medical Devices

Disc Medicine's promising EPP drug hits a major roadblock as the FDA seeks more data, delaying hope for patients and setting up a high-stakes trial.

With a $15 million funding boost, Nasus Pharma is accelerating its powder-based intranasal epinephrine, NS002, challenging the EpiPen's dominance.

A new online pharmacy is challenging the 'prescribe and forget' model for weight loss drugs, offering integrated clinical care to combat safety concerns.

Irish firm InVera Medical wins CE Mark for a new varicose vein device, promising a less invasive, office-based treatment for a widespread condition.

STADA and Bio-Thera's new golimumab biosimilar wins European approval, promising to slash healthcare costs and expand treatment access for millions.

With a year of strong growth, key partnerships, and pipeline progress, all eyes are on ALK's upcoming annual results for 2025.

Aktiia's Hilo adds sleep and step tracking to its validated blood pressure monitor, promising a holistic view of heart health in a competitive market.

Finnish medtech firm Bioretec reports staggering 2025 losses but bets its future on breakthrough implant technology and a complete strategic overhaul.

A new 'longevity center' in Naperville signals a growing trend in proactive health, but what does this mean for the Chicago wellness landscape?

Aethlon Medical advances its Hemopurifier for oncology and Long COVID, but a shrinking cash reserve and rising quarterly loss test its lean science strategy.

Investors eye Globus Medical's upcoming report for a full-year look at its NuVasive integration, market trends, and a pivotal 2025 performance.

With a promising heart failure drug in trials, the biotech aims to woo investors at the Oppenheimer conference to fund its attack on age-related diseases.

Helsinki pioneers a revolutionary cancer therapy, offering new hope with a targeted neutron beam that destroys tumors in just one or two sessions.

A 37-year-old patient receives a successful heart transplant at UCSF after being sustained by a SynCardia Total Artificial Heart, a major clinical win.

A Canadian-made prostate treatment wins a major innovation award as new U.S. Medicare reimbursement positions it for explosive market growth.

A new oral drug, IMSB301, offers hope for Aicardi Goutières Syndrome, a devastating rare disease with no cure, in a pivotal new clinical trial.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.

Align Partners launches a major governance overhaul campaign at Dentium, aiming to fix the 'Korea discount' and unlock value at the undervalued market leader.

With promising new data for its cancer and obesity pipeline, Corbus Pharmaceuticals prepares for a crucial investor presentation at the Oppenheimer conference.

A new diagnostic tool for interstitial lung disease receives FDA Fast Track, promising earlier, more accurate detection of deadly lung inflammation.